Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03873324
Other study ID # 01PDE2018
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date December 20, 2018
Est. completion date September 16, 2019

Study information

Verified date October 2019
Source Celon Pharma SA
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The planned study is to determine the safety and pharmacokinetic properties of CPL500036 compound after single and multiple (two weeks) administration in healthy volunteers.


Description:

This is to be one-centre, single ascending dose and double-blind multiple ascending dose two part study of CPL500036 compound in healthy volunteers.

PART A is a single dose, open-label part with CPL500036 compound administered with dose escalation between cohorts.

PART B is a multiple, double-blind part with CPL500036 compound administered for 14 days with dose escalation between cohorts. Participants in this part are to be randomized to receive Investigational Medicinal Product (IMP) or placebo in 3:1 ratio.

Safety and pharmacokinetic properties of CPL500036 compound is to be determined following different doses in single oral IMP administration in PART A and different doses of IMP administered orally for two weeks in PART B.


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date September 16, 2019
Est. primary completion date September 16, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Caucasian female or male,

- Age: 18-55 years old, inclusive,

- Body-mass index (BMI): =18.5 kg/m^2 and <29.9 kg/m^2,

- Non-smoker and nonuser of tobacco products for at least 3 months before screening,

- Physical examination without any clinically relevant abnormality,

- Laboratory values not clinically significant,

- Volunteer (or his/her partner) of childbearing potential willingness to use acceptable forms of contraception.

Exclusion Criteria:

- Known allergy or hypersensitivity to other drugs similar in structure or class to CPL500036 compound, or to any excipients of the formulation,

- Any known significant current or past acute or chronic disease or condition,

- Participation in other clinical trial within 90 days preceding the screening,

- Blood drawn within 30 days prior to inclusion to the study (more or equal to 300mL),

- Positive results from pregnancy test for female participants,

- Lactation in women participants,

- Hypotension or hypertension in medical history,

- Long QT interval syndrome or is under the treatment with antiarrhythmic drugs,

- Narcotic, alcohol addiction or abuse,

- Participant who adhere to a special diet (e.g. low calories, vegetarian).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CPL500036 compound
IMP is a capsule with CPL500036 as an Active Pharmaceutical Ingredient (API).
Placebo
matching placebo capsules

Locations

Country Name City State
Poland BioResearch Group Sp. z o.o. Kajetany Nadarzyn

Sponsors (2)

Lead Sponsor Collaborator
Celon Pharma SA National Center for Research and Development, Poland

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determination of maximum tolerated dose (MTD) or administration of the maximum dose provided in the protocol after single and multiple oral administration of IMP. MTD is defined as the highest dose for which no more than 1 of the 6 treated volunteers (less than 1/3) exhibits dose limiting toxicity (DLT). up to 24 hours after single administration of IMP in PART A and up to 24 hours after the last IMP administration in PART B
Primary Safety and tolerability of IMP after single and multiple oral administration based on laboratory values, vital signs, ECG, physical examinations and Adverse Events monitoring. Participants are to be closely observed to assure maximal safety and to collect occurrence of all adverse events. All participants are to be monitored for clinically relevant changes in physical examination, vital signs, 12-lead ECG assessment and deviations from normal in clinical laboratory results (complete blood count, blood chemistry, urinalysis). To follow-up on all study participants telephone calls with a request for information regarding their health condition are to be made. up to 14 days in PART A and up to 28 days in PART B of the study
Secondary Cmax - maximum CPL500036 plasma concentration The maximum concentration of the CPL500036 compound in plasma after IMP administration, obtained directly from the measured concentrations. up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B
Secondary AUC(0-72) - area under the plasma concentration - time curve from time 0 to 72h after IMP administration for CPL500036 The AUC(0-72) is a measure of total plasma exposure to the drug from time point zero to 72 hours after IMP administration. up to 72 hours after administration of IMP in PART A
Secondary AUC(0-24) - area under the plasma concentration - time curve from time 0 to 24h after IMP administration for CPL500036 The AUC(0-24) is a measure of total plasma exposure to the drug from time point zero to 24 hours after IMP administration. up to 24 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 and 14 in PART B
Secondary AUC(0-inf) - area under the plasma concentration - time curve from time 0 to infinity time for CPL500036 The AUC(0-inf) is a measure of total plasma exposure to the drug from time point zero extrapolated to infinity. up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B
Secondary Tmax - time to reach maximum CPL500036 concentration The Tmax is time to reach the maximum plasma concentration (Cmax), obtained directly from the actual sampling times. up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B
Secondary Kel - terminal elimination rate constant Kel is to be estimated via linear regression of time versus log of concentration. up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B
Secondary T1/2 - The plasma elimination half-life for CPL500036 compound T1/2 is to be calculated as 0.693/Kel. up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B
Secondary C (1,t) - CPL500036 concentration The concentration of CPL500036 on day t before product administration. Determined on Day 2, 3, 4, 5, 6, 8, 9, 10, 11, 12 and 13 in PART B.
Secondary C (Tmax, t) - CPL500036 concentration The concentration on day t measured on time Tmax which was calculated in PART A of the study. Determined on Day 2, 3, 4, 5, 6, 8, 9, 10, 11, 12 and 13 in PART B.
Secondary Amount of CPL500036 in each urine collection sample It is to be calculated as CPL500036 concentration in urine sample times volume of urine collection. up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B
Secondary Ae - total amount of CPL500036 excreted in urine Ae is to be calculated as asymptote of the plot of the cumulative amount of drug excreted after each collection interval plotted against the median of the collection interval. up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B
Secondary Clr - renal clearance Clr is to be calculated by linear least squares regression analysis on semi-logarithmic transformed data (CLr = excretion rate/C). up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B
Secondary Excretion rate Excretion rate calculated as = CLr/V x Dose x exp(-kt) up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1